hpc for biotech startups maggie goiser

2.12.2024

EuroCC provides access to supercomputers for biotech startups


auf Deutsch
 

Bioinformatics and supercomputing go together like Google and search – and everyone knows that computing resources can sometimes be scarce. EuroCC Austria, the national competence centre for supercomputing, big data, and AI, offers free access to the Austrian supercomputer VSC as well as biotech expertise for startups and SMEs. Bioinformatician Malgorzata Goiser explains how this works in practice.

Interview by Bettina Benesch

Maggie, how do you support startups and SMEs in the field of bioinformatics?


I deal with questions in the field of bioinformatics that users at the Vienna Scientific Cluster (VSC) might have. I provide consulting to those who are just getting started with supercomputing or want to set up a new project. This includes advice on the tools they can use. Bioinformatics is a constantly evolving field. Our expertise at EuroCC lies in quickly passing on these changes to our users. Additionally, I’m always on the lookout for partners who either need High-Performance Computing (HPC) resources or have expertise that our clients can benefit from.

Many people are unaware that we have a supercomputer in Austria that is open to any company. We also facilitate access to HPC systems across all Europe.

What fascinates you most about your work?


I love inspiring people to embrace HPC. Many don’t realise that Austria has a supercomputer that is essentially open to any company – not to mention the other European systems to which every company in the region can gain access. I think this is an opportunity that should be taken advantage of because HPC can make a significant contribution and drive innovation across Europe.


Who is the typical customer of EuroCC Austria?


We primarily work with startups and SMEs, but we welcome anyone who doesn’t have their own cluster or access to one. What makes EuroCC special is that the project enables access to high-performance computers across Europe, including pre-exascale systems currently located in Finland, Italy, and Spain.


Which applications in bioinformatics require High-Performance Computing?


Typically, these involve analysing sequenced data in genetics or proteomics. In the past, predicting protein structures in the lab, for example, was very tedious – now, thanks to AlphaFold and similar tools, it works quite quickly and with high predictive accuracy.


What’s happening right now in the field of bioinformatics and artificial intelligence (AI)?
 

A project is currently in progress that aims to consolidate everything ever researched in the life sciences.

One project currently in progress, which I find very exciting, is the consolidation of everything ever researched in the life sciences. The goal is to integrate everything ever written in this field into an AI system to identify connections. Of course, this is an extremely demanding project because the texts need to be validated first. It will take a long time before AI can be widely implemented.
 

What challenges does healthcare face in connection with bioinformatics?


As a bioinformatician, I would love to have access to a large amount of patient data: age, gender, medical histories, diagnostic values, genetic data, and so on. Much of this is protected by privacy laws, and patients must consent to share it. So, data is a scarce resource.
 

Does that mean bioinformaticians would like to have more data?


Yes. If we had information on lifestyle and living conditions alongside clinical diagnoses, research could take a huge leap forward. We know that our genes only play a partial role in the development of diseases. Everything else is epigenetics – the environment and living conditions. This would involve an enormous number of factors, and working with them would be an exciting and immensely important project for humanity. That would be a dream, and I’d love to analyse it.
 

Until then – if that day ever comes – does research just make do with the data available?
 

Thankfully, there are people willing to share their data, and even with that, a lot can already be discovered.
 

Where do you think bioinformatics is heading with HPC, HPDA, and AI?


AI will certainly have a major impact on healthcare. There will probably always be basic research, but everything will likely move faster with AI tools. Bioinformatics is a very broad field. For example, it’s possible to analyse every stressor in every conceivable configuration. The possibilities are endless.


If you had one wish, what would it be?
 

Patient data is protected by privacy laws, and patients must consent to share it. So, data is a scarce resource.

It’s about data: there are many doctors and scientists who have an incredible amount of data stored away. I’m convinced that we could achieve a great deal if this data were analysed. So, here’s a call to anyone with data who doesn’t know what to do with it: come to us, let us analyse it. Your data could make a significant contribution.


Short bio

Malgorzata Goiser began her career as a bioinformatician at the Medical University of Vienna and subsequently worked eight years at the Vienna BioCenter. Since 2021, she has been with EuroCC as an expert in HPC and High-Performance Data Analysis (HPDA), responsible for connecting HPC experts with HPC users. She supports entrepreneurs in running their biotech projects on Austria’s supercomputer, the VSC.


About the key concepts